Who was studied, and how
Six numbers in the abstract
Where each one falls
Where it lands on the map
5,394people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
300 mg canagliflozin
100 mg canagliflozin
No clear effect on urinary tract infections−7%
No clear effect on postural dizziness1.5×
No clear effect on hypoglycemia−4%
randomisedthe abstract, start to end
… were also similarly manifested, with OR: 0.93, 95% CI: 0.70-1.23; P = 0.61, OR: 1.51, 95% CI: 0.42-5.37; P = 0.53 and OR: 0.96, 95% CI: 0.81-1.13; P = 0.60 …
… 100 or 300 mg canagliflozin with OR: 1.13, 95% CI: 0.43-2.94; P = 0.80.
… this unequal follow-up period with OR: 1.35, 95% CI: 1.06-1.72; P = 0.01, …
… by 300 mg canagliflozin, with OR: 1.01, 95% CI: 0.79-1.29; P = 0.93.
← favours treatmentfavours comparator →
could be chanceUrinary tract infections300 mg canagliflozin vs 100 mg canagliflozin
OR 0.930.70–1.23
Postural dizziness300 mg canagliflozin vs 100 mg canagliflozin
OR 1.510.42–5.37
Hypoglycemia300 mg canagliflozin vs 100 mg canagliflozin
OR 0.960.81–1.13
Death300 mg canagliflozin vs 100 mg canagliflozin
OR 1.130.43–2.94
Drug discontinuation due to AEs300 mg canagliflozin vs 100 mg canagliflozin
OR 1.351.06–1.72
Serious AEs300 mg canagliflozin vs 100 mg canagliflozin
OR 1.010.79–1.29
SGLT2 inhibitorsAll-cause mortalityAdverse events & safetyHypoglycaemia
1 / 4